Monod Bio Analysis: $25M Raised
What is Monod Bio?
AI-powered de novo protein biosensors for clinical diagnostics
Location
Seattle, United States
Employees
11-50
Founded
2021
Product Features & Capabilities
- NovoBody biosensors for targeted detection
- LuxSit™ Pro platform for real-time analytical assays
- NovoLISA for label-free immunoassays
- AI-driven protein design engine for de novo biosensor creation
Use Cases
Detect biomarkers in patient blood samples with 90% sensitivity; Enable real-time monitoring of drug concentrations in clinical trials; Perform label-free immunoassays with 95% accuracy; Develop custom biosensors for rare disease diagnostics; Automate biosensor validation workflows for R&D teams
Other Considerations
Founded by ex-DeepMind and ex-DeepMind researchers; Technology based on de novo protein design; Focus on modular, reusable biosensing nanoswitches; Targets clinical diagnostics and point-of-care applications
See something that needs updating? Suggest edits to this profile.